Spago Nanomedical to be granted US patent for Tumorad®
Spago Nanomedical have received a Notice of Allowance indicating that the United States Patent and Trademark Office (USPTO) intend to grant the company´s patent application comprising product protection for Tumorad® in the USA.The patent (Nanostructures and applications thereof, 15/129,229) means that Spago Nanomedical gains product protection for Tumorad® in the USA, one of the strategically most important markets for radionuclide therapies. It includes the company´s unique nanoparticles and will secure market exclusivity in the USA until at least 2035. ”Strong patents are key